The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
Open accessAbstract
An impressive clinical success has been observed in treating a variety of cancers using immunotherapy with programmed cell death‐1 (PD‐1) checkpoint blockade. However, limited response in most patients treated with anti‐PD‐1 antibodies remains a challenge, requiring better understanding of molecular mechanisms limiting immunotherapy. In colorectal cancer (CRC) resistant to immunotherapy, mismatch‐repair‐proficient or microsatellite instability‐low (pMMR‐MSI‐L) tumors have low mutation burden and constitute ~85% of patients. Here, we show that inhibition of N 6 ‐methyladenosine (m 6 A) mRNA modification by depletion of methyltransferases, Mettl3 and Mettl14, enhanced response to anti‐PD‐1 treatment in pMMR‐MSI‐L CRC and melanoma. Mettl3‐ or Mettl14‐deficient tumors increased cytotoxic tumor‐infiltrating CD8 + T cells and elevated secretion of IFN‐γ, Cxcl9, and Cxcl10 in tumor microenvironment in vivo . Mechanistically, Mettl3 or Mettl14 loss promoted IFN‐γ‐Stat1‐Irf1 signaling through stabilizing the Stat1 and Irf1 mRNA via Ythdf2. Finally, we found a negative correlation between METTL3 or METTL14 and STAT1 in 59 patients with pMMR‐MSI‐L CRC tumors. Altogether, our findings uncover a new awareness of the function of RNA methylation in adaptive immunity and provide METTL3 and METTL14 as potential therapeutic targets in anticancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…practice of ICIs for tumors with high mutation burden, such as non-small cell lung cancer (NSCLC) and melanoma, while the failure of response or elapse in low-mutation-burden cancer patients treated with ICIs remains common (Alexandrov et al , 2013; Sharma et al , 2017; Ganesh et al , 2019).”
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 7×
“Among these negative regulatory pathways, PD-1 (programmed cell death – 1) and CTLA-4 (cytotoxic T-lymphocyte protein 4) have been targeted by immune checkpoint inhibitors (ICIs) to enhance tumor cell killing by T cells in immunotherapy (Jenkins et al , 2018).”
InfluentialCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“…recognition of the major histocompatibility complex (MHC) complex-peptides presented on target cells, e.g., tumor cell, and T cell receptors (TCR) on immune cells (Schreiber et al , 2011; Khalil et al , 2016), whereas this recognition alone is not sufficient for initiation of the immune response.”
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012) · Cell · doi:10.1016/j.cell.2012.05.003 · Cited by 4,223
Cited by
The role of m6A RNA methylation in cancer metabolism
An, Y., & Duan, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01500-4 · Cited by 871
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Wan, W., Ao, X., Chen, Q., Yu, Y., Ao, L., Xing, W., Guo, W., Wu, X., Pu, C., Hu, X., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01447-y · Cited by 457
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 405
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Deng, L.-J., Deng, W.-Q., Fan, S.-R., Chen, M.-F., Qi, M., Lyu, W.-Y., Qi, Q., Tiwari, A. K., Chen, J.-X., Zhang, D.-M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01510-2 · Cited by 366
The roles and implications of RNA m6A modification in cancer
Deng, X., Qing, Y., Horne, D., Huang, H., & Chen, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00774-x · Cited by 364
Hidden codes in mRNA: Control of gene expression by m6A
Murakami, S., & Jaffrey, S. R. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.05.029 · Cited by 292
Li, N., Hui, H., Bray, B., Gonzalez, G. M., Zeller, M., Anderson, K. G., Knight, R., Smith, D., Wang, Y., Carlin, A. F., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109091 · Cited by 275
Self-citationN6-methyladenosine methyltransferases: functions, regulation, and clinical potential
Huang, W., Chen, T.-Q., Fang, K., Zeng, Z.-C., Ye, H., & Chen, Y.-Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01129-8 · Cited by 275
Wu, S., Yun, J., Tang, W., Familiari, G., Relucenti, M., Wu, J., Li, X., Chen, H., & Chen, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c03050 · Cited by 102
Metadata
- Authors
- Wang, L., Hui, H., Agrawal, K., Kang, Y., Li, N., Tang, R., Yuan, J., & Rana, T. M.
- Venue
- The EMBO Journal
- Published
- 2020-09-23
- Volume
- 39
- Issue
- 20
- Pages
- e104514-e104514
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W3088329595
- Cited by
- 407
- References
- 70
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.